Inova Labs receives CE Mark Approval for the LifeChoice® Portable Oxygen Concentrator System - Gilde Healthcare

Menu
Menu
Home

Inova Labs receives CE Mark Approval for the LifeChoice® Portable Oxygen Concentrator System

December 1, 2011

New Technology enables COPD patients to experience true portability while maintaining appropriate oxygen concentration levels during both day and night

Austin, TX – Inova Labs, a privately held medical device company focused on developing innovative products for the Chronic Obstructive Pulmonary Disease (COPD) Market, announced today that it has received CE Mark approval to begin marketing the LifeChoice® Portable Oxygen Concentrator System in Europe.

“This is a major milestone for our Company and for COPD patients who are on Long Term Oxygen Therapy,” said John Rush, CEO of Inova Labs.   “The LifeChoice® technology allows patients to continue to live their daily lives with minimal disruption despite the advanced stage of their COPD disease.”

The Company is currently in discussions with potential partners in Europe and expects to begin marketing the LifeChoice® Technology in the region in early 2012.

– Ends –

About Inova Labs

Inova Labs is an Austin, Texas based medical device company which develops and commercializes innovative products for the COPD market.  The company is currently marketing the LifeChoice® Portable Oxygen Concentrator System, which is the lightest and smallest oxygen concentrator on the market with FDA approval for continuous use by patients.   LifeChoice® delivers oxygen to the COPD patient using a proprietary “Pulse Wave” technology, which insures that the patient receives maximum benefit from the oxygen produced.  LifeChoice® also offers “Auto Mode” technology which enables the patient to automatically receive the prescribed oxygen dose during periods of activity as well as sleep.  The product is approved by FAA for air travel and is manufactured under strict ISO certification guidelines.

More news

Gilde Healthcare participates in $150M Series D financing of CatalYm

Proceeds will expand late-stage clinical development of lead programme visugromab’s into earlier lines of treatment including checkpoint naïve and second-line settings in randomized, controlled studies in select solid tumor indications Round brings on board new international...
July 16, 2024

Gilde Healthcare portfolio company Eetgemak joins forces with TotaalVERS to become the leading integrated healthcare foodservice provider

Combining TotaalVERS and Eetgemak will form a leading end-to-end foodservice provider*, offering a wide range of convenience meals, ingredients and groceries to the healthcare sector. The partnership emphasizes commitment to quality, service, and innovation in...
July 5, 2024

Gilde Healthcare company Volta Medical announces positive results from transatlantic trial on AI-assisted ablation for persistent atrial fibrillation

TAILORED-AF randomized controlled trial (RCT) findings demonstrated superiority in freedom from atrial fibrillation (AF) at 12 months from a tailored cardiac ablation guided by artificial intelligence (AI) when compared to pulmonary vein isolation (PVI) alone....
May 21, 2024